Cargando…
Antituberculosis Drug-Induced Fixed Drug Eruption: A Case Report
Fixed drug eruption (FDE) was caused by fixed-dose combination (FDC) of antituberculosis drugs in the form of tablet Forecox(®) (rifampicin [rifampin] 225 mg + isoniazid 150 mg + pyrazinamide 750 mg + ethambutol 400 mg) in a 40-year-old male patient with a history of drug allergy. The patient develo...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5962523/ https://www.ncbi.nlm.nih.gov/pubmed/29785553 http://dx.doi.org/10.1007/s40800-018-0086-z |
_version_ | 1783324880702275584 |
---|---|
author | Vaghela, Jitendra H. Nimbark, Vivek Barvaliya, Manish Mehta, Hita Chavada, Bhavesh |
author_facet | Vaghela, Jitendra H. Nimbark, Vivek Barvaliya, Manish Mehta, Hita Chavada, Bhavesh |
author_sort | Vaghela, Jitendra H. |
collection | PubMed |
description | Fixed drug eruption (FDE) was caused by fixed-dose combination (FDC) of antituberculosis drugs in the form of tablet Forecox(®) (rifampicin [rifampin] 225 mg + isoniazid 150 mg + pyrazinamide 750 mg + ethambutol 400 mg) in a 40-year-old male patient with a history of drug allergy. The patient developed FDE after taking the third dose of tablet Forecox(®) for pulmonary tuberculosis. Tablet Forecox(®) was withdrawn and the patient recovered from the reaction after 15 days of treatment for FDE. As per World Health Organization–Uppsala Monitoring Centre (WHO-UMC) and Naranjo causality assessment criteria, the association between the reaction and tablet Forecox(®) was possible and probable, respectively. The reaction was moderately (Level 4b) severe according to the Modified Hartwig and Siegel scale. As there is an increased risk of allergic reaction in patients with a history of drug allergy, FDCs should not be used in order to avoid complexity in identifying the culprit drug. |
format | Online Article Text |
id | pubmed-5962523 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-59625232018-06-04 Antituberculosis Drug-Induced Fixed Drug Eruption: A Case Report Vaghela, Jitendra H. Nimbark, Vivek Barvaliya, Manish Mehta, Hita Chavada, Bhavesh Drug Saf Case Rep Case Report Fixed drug eruption (FDE) was caused by fixed-dose combination (FDC) of antituberculosis drugs in the form of tablet Forecox(®) (rifampicin [rifampin] 225 mg + isoniazid 150 mg + pyrazinamide 750 mg + ethambutol 400 mg) in a 40-year-old male patient with a history of drug allergy. The patient developed FDE after taking the third dose of tablet Forecox(®) for pulmonary tuberculosis. Tablet Forecox(®) was withdrawn and the patient recovered from the reaction after 15 days of treatment for FDE. As per World Health Organization–Uppsala Monitoring Centre (WHO-UMC) and Naranjo causality assessment criteria, the association between the reaction and tablet Forecox(®) was possible and probable, respectively. The reaction was moderately (Level 4b) severe according to the Modified Hartwig and Siegel scale. As there is an increased risk of allergic reaction in patients with a history of drug allergy, FDCs should not be used in order to avoid complexity in identifying the culprit drug. Springer International Publishing 2018-05-21 /pmc/articles/PMC5962523/ /pubmed/29785553 http://dx.doi.org/10.1007/s40800-018-0086-z Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Case Report Vaghela, Jitendra H. Nimbark, Vivek Barvaliya, Manish Mehta, Hita Chavada, Bhavesh Antituberculosis Drug-Induced Fixed Drug Eruption: A Case Report |
title | Antituberculosis Drug-Induced Fixed Drug Eruption: A Case Report |
title_full | Antituberculosis Drug-Induced Fixed Drug Eruption: A Case Report |
title_fullStr | Antituberculosis Drug-Induced Fixed Drug Eruption: A Case Report |
title_full_unstemmed | Antituberculosis Drug-Induced Fixed Drug Eruption: A Case Report |
title_short | Antituberculosis Drug-Induced Fixed Drug Eruption: A Case Report |
title_sort | antituberculosis drug-induced fixed drug eruption: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5962523/ https://www.ncbi.nlm.nih.gov/pubmed/29785553 http://dx.doi.org/10.1007/s40800-018-0086-z |
work_keys_str_mv | AT vaghelajitendrah antituberculosisdruginducedfixeddrugeruptionacasereport AT nimbarkvivek antituberculosisdruginducedfixeddrugeruptionacasereport AT barvaliyamanish antituberculosisdruginducedfixeddrugeruptionacasereport AT mehtahita antituberculosisdruginducedfixeddrugeruptionacasereport AT chavadabhavesh antituberculosisdruginducedfixeddrugeruptionacasereport |